Genetic Changes of Wnt Pathway Genes Are Common Events in Metaplastic Carcinomas of the Breast

• Published in: Clinical cancer research 2008-07, Vol.14 (13), p.4038-4044
• Main Authors: HAYES, Michael J, THOMAS, Dafydd, EMMONS, Agnieszka, GIORDANO, Thomas J, KLEER, Celina G
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Antineoplastic agents; Biological and medical sciences; breast cancer; Breast Neoplasms - genetics; Breast Neoplasms - pathology; Carcinoma - genetics; Carcinoma - pathology; CCN6; Cell Differentiation; Cell Lineage; differentiation; DNA Mutational Analysis; DNA Primers - chemistry; epithelial to mesenchymal transition; Female; Gene Expression Regulation, Neoplastic; Humans; Medical sciences; metaplastic carcinoma; Middle Aged; Mutation, Missense; Pharmacology. Drug treatments; stem cells; WISP3; Wnt; Wnt Proteins - metabolism; β-catenin
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-07-4379

Purpose: Metaplastic carcinomas are distinct invasive breast carcinomas with aberrant nonglandular differentiation, which may be spindle, squamous, or chondroid. The limited effective treatments result from the lack of knowledge of its molecular etiology. Given the role of the Wnt pathway in cell fate and in the development of breast cancer, we hypothesized that defects in this pathway may contribute to the development of metaplastic carcinomas. Design: In 36 primary metaplastic carcinomas, we comprehensively determined the prevalence of and mechanism underlying β-catenin and Wnt pathway deregulation using immunohistochemistry for β-catenin expression and localization and mutational analysis for CTNNB1 (encoding β-catenin), APC, WISP3, AXIN1 , and AXIN2 genes. By immunohistochemistry, normal β-catenin was seen as membrane staining, and it was aberrant when >5% of tumor cells had nuclear or cytoplasmic accumulation or reduced membrane staining. Results: By immunohistochemistry, aberrant β-catenin was present in 33 of 36 (92%) cases, revealing deregulation of the Wnt pathway. CTNNB1 missense mutations were detected in 7 of 27 (25.9%) tumors available for mutation analyses. All mutations affected the NH 2 -terminal domain of β-catenin, presumably rendering the mutant protein resistant to degradation. Two of 27 (7.4%) tumors had mutations of APC , and 5 (18.5%) carried a frame shift mutation of WISP3. No AXIN1 or AXIN2 mutations were found. Conclusions: Activation of the Wnt signaling pathway is common in this specific subtype of breast carcinoma. The discovery of CTNNB1, APC , and WISP3 mutations may result in new treatments for patients with metaplastic carcinomas of the breast.